Abstract
Despite epidermal growth factor receptor (EGFR) is a pivotal oncogene for several cancers, including lung adenocarcinoma (LUAD), how it senses extracellular matrix (ECM) rigidity remain elusive in the context of the increasing role of tissue rigidity on various hallmarks of cancer development. Here it is shown that EGFR dictates tumorigenic agrin expression in lung cancer cell lines, genetically engineered EGFR-driven mouse models, and human specimens. Agrin expression confers substrate stiffness-dependent oncogenic attributes to EGFR-reliant cancer cells. Mechanistically, agrin mechanoactivates EGFR through epidermal growth factor (EGF)-dependent and independent modes, thereby sensitizing its activity toward localized cancer cell-ECM adherence and bulk rigidity by fostering interactions with integrin β1. Notably, a feed-forward loop linking agrin–EGFR rigidity response to YAP–TEAD mechanosensing is essential for tumorigenesis. Together, the combined inhibition of EGFR–YAP/TEAD may offer a strategy to reduce lung tumorigenesis by disrupting agrin-EGFR mechanotransduction, uncovering a therapeutic vulnerability for EGFR-addicted lung cancers.
Original language | English |
---|---|
Article number | 2413443 |
Journal | Advanced Science |
Volume | 12 |
Issue number | 20 |
DOIs | |
State | Published - May 29 2025 |
Bibliographical note
Publisher Copyright:© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH.
Funding
The authors thank Dr Wiam Bshara and Leighton Stein from the pathology shared network resources at Roswell Park for immunohistochemistry (IHC) studies. The authors are also grateful to Dr. Deanna Conners for critically reading the manuscript. All cartoons and schematics were prepared using Biorender. This study was funded in\u2010part from core start\u2010up funds and Developmental Therapeutics Grant to S.C, from the Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, and core funds from IMCB to W.H., and R01CA237643 and Biospecimen Procurement and Translational Pathology Shared Resource Facilities P30CA177558 to C.F.B. Editorial assistance for this publication was provided by Roswell Park's Scientific Editing and Research Communications Core (SERCC) Resource, which is supported by a National Cancer Institute (NCI) Cancer Center Support Grant (NCI P30CA016056).
Funders | Funder number |
---|---|
Department of Pharmacology and Experimental Therapeutics | |
SERCC | |
International Institute of Molecular and Cell Biology | P30CA177558, R01CA237643 |
International Institute of Molecular and Cell Biology | |
National Childhood Cancer Registry – National Cancer Institute | P30CA016056 |
National Childhood Cancer Registry – National Cancer Institute |
Keywords
- EGFR, extracellular matrix
- YAP/TAZ
- agrin
- hippo pathway
- lung cancer
ASJC Scopus subject areas
- Medicine (miscellaneous)
- General Chemical Engineering
- General Materials Science
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
- General Engineering
- General Physics and Astronomy